Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics PLC

Biotechnology • Healthcare • Abingdon, United Kingdom • ADAP (NGM)

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

44 12 3543 0000 60 Jubilee Avenue, United Kingdom

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Adaptimmune stock plunges after announcing Nasdaq delisting plans - Investing.com
Investing.com • Oct 20
ADAPTIMMUNE THERAPEUTICS Earnings Preview: Recent $ADAP Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Quiver Quantitative • Dec 5
Why Is Adaptimmune Therapeutics Stock (ADAP) Rising Today? - TipRanks
TipRanks • Oct 9
Adaptimmune Announces Delisting from Nasdaq - TMX Newsfile
TMX Newsfile • Oct 20
Adaptimmune Therapeutics to Delist from Nasdaq by October 27 - MSN
MSN • Jan 3

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Adaptimmune Therapeutics PLC had layoffs?
No layoff events have been recorded for Adaptimmune Therapeutics PLC in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Adaptimmune Therapeutics PLC have?
Adaptimmune Therapeutics PLC has approximately 506 employees.
What industry is Adaptimmune Therapeutics PLC in?
Adaptimmune Therapeutics PLC operates in the Biotechnology industry, within the Healthcare sector.
Is Adaptimmune Therapeutics PLC a publicly traded company?
Yes, Adaptimmune Therapeutics PLC is publicly traded under the ticker symbol ADAP on the NGM. The company has a market capitalization of approximately $0.01 billion.
Where is Adaptimmune Therapeutics PLC headquartered?
Adaptimmune Therapeutics PLC is headquartered in Abingdon, United Kingdom at 60 Jubilee Avenue, United Kingdom.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.